Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease
- PMID: 30851477
- DOI: 10.1016/j.cgh.2019.02.042
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease
Abstract
Ustekinumab is approved for treatment of Crohn's disease (CD).1,2 Few data are available to assess the usefulness of monitoring inflammatory biomarkers and therapeutic drug monitoring to predict response to ustekinumab. We conducted a prospective study to assess the relationships between these parameters and the clinical outcome at week 16 in active CD patients receiving ustekinumab.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical